22nd Century Group, Inc. Announces Allowance of U.S. Patent for MPO Nicotine Biosynthesis Gene

Published: Jan 03, 2013

CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction and smoking cessation products, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the N-methylputrescine oxidase (MPO) gene technology. MPO is essential for production of nicotine in the tobacco plant.

Back to news